SUPN insider transaction filings
SUPERNUS PHARMACEUTICALS, INC. — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-08-14. Screen SUPN transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-14 | 4 | Mottola Frank — SVP, Chief Tech. Ops. Officer | Option exercise (M): 1,650 @ $0 · Tax withholding (F): 797 @ $46.57 · Option exercise (M): 1,650 (derivative) @ $0 | EDGAR |
| 2026-08-14 | 4 | Bhatt Padmanabh P. — Sr. VP of IP, CSO | Option exercise (M): 2,500 @ $0 · Tax withholding (F): 1,158 @ $46.57 · Option exercise (M): 2,500 (derivative) @ $0 | EDGAR |
| 2026-08-14 | 4 | Rubin Jonathan — SVP, Chief Medical Officer | Option exercise (M): 750 @ $0 · Tax withholding (F): 363 @ $46.57 · Option exercise (M): 750 (derivative) @ $0 | EDGAR |
| 2026-08-14 | 4 | Khattar Jack A. — President, CEO, Director | Option exercise (M): 29,849 @ $0 · Tax withholding (F): 12,642 @ $46.57 · Option exercise (M): 29,849 (derivative) @ $0 | EDGAR |
| 2026-08-14 | 4 | DEC TIMOTHY C — Senior Vice-President & CFO | Option exercise (M): 1,250 @ $0 · Tax withholding (F): 604 @ $46.57 · Option exercise (M): 1,250 (derivative) @ $0 | EDGAR |
| 2026-07-31 | 4 | Mottola Frank — SVP, Chief Tech. Ops. Officer | Grant/award (A): 1,650 (derivative) @ $0 | EDGAR |
| 2026-07-31 | 4 | DEC TIMOTHY C — Senior Vice-President & CFO | Grant/award (A): 1,250 (derivative) @ $0 | EDGAR |
| 2026-07-31 | 4 | Khattar Jack A. — President, CEO, Director | Grant/award (A): 29,849 (derivative) @ $0 | EDGAR |
| 2026-07-31 | 4 | Rubin Jonathan — SVP, Chief Medical Officer | Grant/award (A): 750 (derivative) @ $0 | EDGAR |
| 2026-07-31 | 4 | Bhatt Padmanabh P. — Sr. VP of IP, CSO | Grant/award (A): 2,500 (derivative) @ $0 | EDGAR |
| 2026-03-18 | 4 | Bhatt Padmanabh P. — Sr. VP of IP, CSO | Option exercise (M): 22,750 @ $36.75 · Option exercise (M): 4,250 @ $29.61 · Option exercise (M): 18,000 @ $32.20 · Option exercise (M): 5,000 @ $27.94 · Sale (S): 34,114 @ $50.18 · Sale (S): 15,886 @ $50.49 · +16 more | EDGAR |
| 2026-03-16 | 4 | Khattar Jack A. — President, CEO, Director | Other (J): 12,500 · Other (J): 12,500 · Sale (S): 24,138 @ $50.09 · Sale (S): 10,742 @ $51 · Sale (S): 120 @ $51.75 | EDGAR |
| 2026-03-16 | 4 | Hudson Frederick M. — Director | Sale (S): 5,369 @ $50.61 | EDGAR |
| 2026-03-10 | 4 | Horich William Todd — SVP, Commercial Operations | Option exercise (M): 2,625 @ $0 · Tax withholding (F): 1,216 @ $54.73 · Option exercise (M): 3,750 @ $0 · Tax withholding (F): 1,718 @ $54.73 · Option exercise (M): 1,125 @ $0 · Tax withholding (F): 521 @ $54.73 · +5 more | EDGAR |
| 2026-03-10 | 4 | Mottola Frank — SVP, Chief Tech. Ops. Officer | Option exercise (M): 3,750 @ $0 · Tax withholding (F): 1,793 @ $54.73 · Sale (S): 1,623 @ $53.65 · Option exercise (M): 3,750 (derivative) @ $0 | EDGAR |
| 2026-03-10 | 4 | Khattar Jack A. — President, CEO, Director | Option exercise (M): 38,640 @ $0 · Tax withholding (F): 16,574 @ $54.73 · Option exercise (M): 38,640 (derivative) @ $0 | EDGAR |
| 2026-03-10 | 4 | DEC TIMOTHY C — Senior Vice-President & CFO | Option exercise (M): 3,000 @ $0 · Tax withholding (F): 1,433 @ $54.73 · Option exercise (M): 3,000 @ $0 · Tax withholding (F): 1,450 @ $54.73 · Option exercise (M): 3,000 (derivative) @ $0 · Option exercise (M): 3,000 (derivative) @ $0 | EDGAR |
| 2026-03-09 | 4 | GEMAYEL GEORGES — Director | Sale (S): 10,000 @ $53.71 · Option exercise (M): 7,905 @ $25.30 · Sale (S): 8,787 @ $53 · Option exercise (M): 7,905 (derivative) @ $0 | EDGAR |
| 2026-03-03 | 4 | Mottola Frank — SVP, Chief Tech. Ops. Officer | Grant/award (A): 3,750 (derivative) @ $0 | EDGAR |
| 2026-03-03 | 4 | Khattar Jack A. — President, CEO, Director | Grant/award (A): 38,640 (derivative) @ $0 | EDGAR |
| 2026-03-03 | 4 | DEC TIMOTHY C — Senior Vice-President & CFO | Grant/award (A): 3,000 (derivative) @ $0 · Grant/award (A): 3,000 (derivative) @ $0 | EDGAR |
| 2026-02-26 | 4 | Rubin Jonathan — SVP, Chief Medical Officer | Grant/award (A): 1,250 @ $0 · Tax withholding (F): 675 @ $50.69 · Disposition to issuer (D): 1,250 (derivative) @ $0 | EDGAR |
| 2026-02-26 | 4 | Mottola Frank — SVP, Chief Tech. Ops. Officer | Grant/award (A): 1,875 @ $0 · Tax withholding (F): 977 @ $50.69 · Disposition to issuer (D): 1,875 (derivative) @ $0 | EDGAR |
| 2026-02-26 | 4 | Bhatt Padmanabh P. — Sr. VP of IP, CSO | Grant/award (A): 1,250 @ $0 · Tax withholding (F): 650 @ $50.69 · Disposition to issuer (D): 1,250 (derivative) @ $0 | EDGAR |
| 2026-02-26 | 4 | DEC TIMOTHY C — Senior Vice-President & CFO | Grant/award (A): 2,500 @ $0 · Tax withholding (F): 1,279 @ $50.69 · Disposition to issuer (D): 2,500 (derivative) @ $0 | EDGAR |
| 2026-02-25 | 4 | Rubin Jonathan — SVP, Chief Medical Officer | Grant/award (A): 1,125 @ $0 · Tax withholding (F): 603 @ $51.35 · Grant/award (A): 750 @ $0 · Tax withholding (F): 369 @ $50.86 · Grant/award (A): 1,250 @ $0 · Tax withholding (F): 671 @ $0 · +3 more | EDGAR |
| 2026-02-25 | 4 | Mottola Frank — SVP, Chief Tech. Ops. Officer | Grant/award (A): 1,125 @ $0 · Tax withholding (F): 603 @ $51.35 · Grant/award (A): 750 @ $0 · Tax withholding (F): 368 @ $50.86 · Grant/award (A): 1,250 @ $0 · Tax withholding (F): 670 @ $50.86 · +3 more | EDGAR |
| 2026-02-25 | 4 | Barlow Carrolee — Director | Grant/award (A): 4,475 @ $0 · Disposition to issuer (D): 4,475 (derivative) @ $0 | EDGAR |
| 2026-02-25 | 4 | Bhatt Padmanabh P. — Sr. VP of IP, CSO | Grant/award (A): 1,125 @ $0 · Tax withholding (F): 581 @ $51.35 · Grant/award (A): 750 @ $0 · Tax withholding (F): 354 @ $50.86 · Grant/award (A): 1,250 @ $0 · Tax withholding (F): 646 @ $50.86 · +3 more | EDGAR |
| 2026-02-25 | 4 | Hudson Frederick M. — Director | Grant/award (A): 4,475 @ $0 · Disposition to issuer (D): 4,475 (derivative) @ $0 | EDGAR |
| 2026-02-25 | 4 | GEMAYEL GEORGES — Director | Option exercise (M): 15,000 @ $12.98 · Grant/award (A): 4,475 @ $0 · Option exercise (M): 15,000 (derivative) @ $0 · Disposition to issuer (D): 4,475 (derivative) @ $0 | EDGAR |
| 2026-02-25 | 4 | DEC TIMOTHY C — Senior Vice-President & CFO | Grant/award (A): 1,125 @ $0 · Tax withholding (F): 603 @ $51.35 · Grant/award (A): 500 @ $0 · Tax withholding (F): 242 @ $50.86 · Grant/award (A): 3,000 @ $0 · Tax withholding (F): 1,524 @ $50.86 · +3 more | EDGAR |
| 2026-02-25 | 4 | NEWHALL CHARLES W III — Director | Grant/award (A): 4,475 @ $0 · Disposition to issuer (D): 4,475 (derivative) @ $0 | EDGAR |
| 2026-02-23 | 4 | Sensenig Bethany — Director | Option exercise (M): 4,475 @ $0 · Sale (S): 1,217 @ $50.31 · Sale (S): 3,258 @ $51.27 · Option exercise (M): 4,475 (derivative) @ $0 | EDGAR |
| 2026-02-20 | 4 | Sensenig Bethany — Director | Grant/award (A): 2,989 (derivative) @ $0 · Grant/award (A): 4,977 (derivative) @ $0 | EDGAR |
| 2026-02-20 | 4 | Rubin Jonathan — SVP, Chief Medical Officer | Grant/award (A): 13,500 (derivative) @ $0 · Grant/award (A): 3,000 (derivative) @ $0 | EDGAR |
| 2026-02-20 | 4 | Mottola Frank — SVP, Chief Tech. Ops. Officer | Grant/award (A): 13,500 (derivative) @ $0 · Grant/award (A): 3,000 (derivative) @ $0 | EDGAR |
| 2026-02-20 | 4 | Barlow Carrolee — Director | Grant/award (A): 2,989 (derivative) @ $0 · Grant/award (A): 4,977 (derivative) @ $0 | EDGAR |
| 2026-02-20 | 4 | Khattar Jack A. — President, CEO, Director | Grant/award (A): 341,610 (derivative) @ $0 | EDGAR |
| 2026-02-20 | 4 | Bhatt Padmanabh P. — Sr. VP of IP, CSO | Grant/award (A): 13,500 (derivative) @ $0 · Grant/award (A): 3,000 (derivative) @ $0 | EDGAR |
| 2026-02-20 | 4 | Hudson Frederick M. — Director | Grant/award (A): 2,989 (derivative) @ $0 · Grant/award (A): 4,977 (derivative) @ $0 | EDGAR |
| 2026-02-20 | 4 | GEMAYEL GEORGES — Director | Grant/award (A): 2,989 (derivative) @ $0 · Grant/award (A): 4,977 (derivative) @ $0 | EDGAR |
| 2026-02-20 | 4 | DEC TIMOTHY C — Senior Vice-President & CFO | Grant/award (A): 17,500 (derivative) @ $0 · Grant/award (A): 3,000 (derivative) @ $0 | EDGAR |
| 2026-02-20 | 4 | NEWHALL CHARLES W III — Director | Grant/award (A): 2,989 (derivative) @ $0 · Grant/award (A): 4,977 (derivative) @ $0 | EDGAR |
| 2026-01-12 | 4 | Hudson Frederick M. — Director | Option exercise (M): 15,000 @ $12.98 · Option exercise (M): 15,000 (derivative) @ $0 | EDGAR |
| 2025-12-22 | 4 | Mottola Frank — SVP, Chief Tech. Ops. Officer | Option exercise (M): 5,000 @ $39.40 · Sale (S): 5,000 @ $50.22 · Option exercise (M): 15,000 @ $25.30 · Sale (S): 15,000 @ $50.47 · Option exercise (M): 5,000 (derivative) @ $0 · Option exercise (M): 15,000 (derivative) @ $0 | EDGAR |
| 2025-12-19 | 4 | Bhatt Padmanabh P. — Sr. VP of IP, CSO | Option exercise (M): 1,500 @ $0 · Sale (S): 710 @ $44.44 · Option exercise (M): 1,500 (derivative) @ $0 | EDGAR |
| 2025-11-24 | 4 | NEWHALL CHARLES W III — Director | Option exercise (M): 15,000 @ $12.98 · Option exercise (M): 15,000 (derivative) @ $0 | EDGAR |
| 2025-11-17 | 4 | Bhatt Padmanabh P. — Sr. VP of IP, CSO | Grant/award (A): 1,500 (derivative) @ $0 | EDGAR |
| 2025-10-10 | 4 | Khattar Jack A. — President, CEO, Director | Option exercise (M): 81,250 @ $25.30 · Sale (S): 58,371 @ $50.55 · Sale (S): 1,529 @ $51.46 · Option exercise (M): 81,250 (derivative) @ $0 | EDGAR |
Recent 8-K events — SUPERNUS PHARMACEUTICALS, INC.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-03 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-03 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-03 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-03 | 8-K | 1.01 — Entry into a Material Definitive Agreement 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-22 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-18 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-20 | 8-K | 2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-05 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-22 | 8-K | 2.02 — Results of Operations and Financial Condition | EDGAR |
| 2026-04-07 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.01 — Completion of Acquisition or Disposition of Assets 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=SUPN returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →